Complete AAV Production System Enables Scalable Gene Therapy Workflows | New
CARLSBAD, California, September 20, 2021 / PRNewswire / – Responding to the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific launched the free Gibco AAV-MAX Helper * production system, a complete and optimized solution which simplifies the AAV vector production workflow. The all-in-one AAV-MAX system increases productivity and profitability by delivering high viral titers using Viral Production Cells 2.0, a novel 293F-derived mammalian cell line documented by cloning.
AAV is crucial in the field of gene therapy; more than 1,300 unique gene therapy products are currently in development, and nearly half depend on AAV. The ability to increase production is essential to reduce costs and accelerate the process from research to commercialization.
“AAV has an efficacy and safety profile that makes it an ideal therapeutic vector and one of the benchmark biological delivery methods for the latest advances in gene therapy,” said Amy butler, President, Biosciences, Thermo Fisher Scientific. “The new AAV production system is part of our end-to-end workflow solutions designed to meet the growing demand for the production of cost-effective and scalable viral vectors. Having access to products and services designed specifically for cell and gene therapy research, with a range of view to clinical manufacturing, empowers our biotechnology and biopharmaceutical partners. “
The AAV-MAX system was developed to adapt from shake flasks to bioreactors. Coupled with the active development of regulatory compliant reagents **, the system is designed to streamline the transition from research to commercial manufacturing. On average, the system allows viral vector researchers and developers to save 25% on plasmid DNA usage and 50% on production costs compared to polyethyleneimine (PEI) -based mammalian production systems. . When used in conjunction with Thermo Fisher’s Expanded portfolio of gene therapy products, developers are able to smoothly transition into commercial production to help deliver therapies to patients.
To learn more about Thermo Fisher’s AAV Workflow Solutions, please visit www.thermofisher.com/aav. To learn more about the free Gibco AAV-MAX Helper AAV production system, please visit www.thermofisher.com/aavmax.
* For research only.
** cGMP will be available with the AAV-MAX Cell Therapy Systems (CTS) production system.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the global leader in the service of science, with annual sales of approximately $ 35 billion. Our mission is to empower our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life science research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing the productivity of their laboratories, we’re here to support them. Our global team of more than 90,000 colleagues deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmacy services through our industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon . For more information, please visit www.thermofisher.com.
Media contact details:
Email: [email protected]
Email: [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/complete-aav-production-system-enables-scalable-gene-therapy-workflows-301380261.html
SOURCE Thermo Fisher Scientific